Avidity Biosciences, Inc. (RNA)
RNA moved a median of +0.03% 30 minutes after news, and +0.08% by the close. How RNA actually reacts to news — the realized, point-in-time move the market made, measured across 453 labeled events over the last three years with zero look-ahead.
RNA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 53% | 453 |
| 30-min | +0.03% | 53% | 453 |
| 60-min | +0.03% | 56% | 453 |
| to close | +0.08% | 55% | 453 |
| Middle 50% of RNA reactions | -0.92% to +0.76% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 453 |
Half of all Avidity Biosciences, Inc. news events land between -0.92% and +0.76% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RNA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 34 | -0.01% | 38% | -0.40% |
| Coverage initiations | 50 | +0.30% | 58% | -1.32% |
| Rating reiterations | 90 | +0.07% | 56% | +0.17% |
| Price-target raises | 17 | +0.49% | 59% | -0.42% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RNA ranks against every other measured name →
That’s how RNA usually reacts — get an email when it moves on news →Email me when RNA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RNA's baseline. Nothing else.
Recent RNA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing | Press release | PR Newswire | +1.94% | — | |
| Atrium Therapeutics Announces $50 Million Private Placement | Press release | PR Newswire | -1.47% | +1.35% | |
| Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.43% | -0.22% | |
| Atrium Therapeutics to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.00% | +2.11% | |
| Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.85% | -2.44% | |
| Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | Press release | PR Newswire | +0.00% | +0.98% | |
| Atrium Therapeutics Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | -0.16% | +5.16% | |
| Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.47% | +4.77% | |
| Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome | Press release | PR Newswire | -0.33% | -0.33% | |
| Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.19% | -0.23% | |
| Atrium Therapeutics Reports First Quarter 2026 Financial Results | Press release | PR Newswire | +2.00% | -1.85% | |
| Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | Press release | PR Newswire | +1.96% | +0.58% | |
| Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -1.54% | -4.99% | |
| Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Press release | PR Newswire | -2.47% | -1.67% | |
| Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference | Press release | PR Newswire | -2.47% | -1.67% | |
| Form 8-K Avidity Biosciences, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.47% | -1.67% | |
| Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders | Press release | PR Newswire | +0.25% | +0.15% | |
| Form 10-K Avidity Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.06% | -0.23% | |
| Form 8-K Avidity Biosciences, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +0.15% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -0.06% | -0.23% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.02% | -0.04% | |
| The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 | Press release | PR Newswire | -0.08% | +0.04% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -0.09% | -0.18% | |
| Form 8-K Avidity Biosciences, For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | -0.38% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.12% | +0.18% | |
| Avidity Biosciences Announces Expected Record Date for Spin-Off | Press release | PR Newswire | +0.12% | +0.18% | |
| Form DEFM14A Avidity Biosciences, | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | +0.26% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.01% | +0.15% | |
| Form PRER14A Avidity Biosciences, | SEC filing · Form PRER14A | SEC EDGAR | +0.13% | +0.11% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.13% | +0.11% | |
| Form 8-K Avidity Biosciences, For: Dec 14 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | +0.19% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.04% | +0.19% | |
| Form PRER14A Avidity Biosciences, | SEC filing · Form PRER14A | SEC EDGAR | +0.11% | +0.22% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.61% | |
| Form PREM14A Avidity Biosciences, For: Nov 24 | SEC filing · Form PREM14A | SEC EDGAR | +0.01% | +0.51% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -0.06% | -0.41% | |
| Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 | Press release | PR Newswire | +0.07% | +0.14% | |
| Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Press release | PR Newswire | +0.04% | +1.20% | |
| Form 10-Q Avidity Biosciences, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.04% | +1.20% | |
| Form 8-K Avidity Biosciences, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | +1.20% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | +0.04% | +1.20% | |
| Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | -0.02% | -0.01% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -0.03% | +0.01% | |
| RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.03% | +0.01% | |
| Form 8-K Avidity Biosciences, For: Oct 25 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | -0.44% | |
| Form DEFA14A Avidity Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -0.23% | -0.44% | |
| Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG | Press release | PR Newswire | -0.23% | -0.44% | |
| RNA STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF AVIDITY BIOSCIENCES, INC. IS FAIR TO SHAREHOLDERS | Press release | GlobeNewswire | -0.23% | -0.44% | |
| Avidity Biosciences to Participate in Upcoming Investor Conference | Press release | PR Newswire | +0.27% | -4.52% | |
| Form 8-K Avidity Biosciences, For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +0.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RNA section they belong to.
Where else RNA is measured.
RNA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Avidity Biosciences, Inc.'s median reaction calculated?
Every labeled RNA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 453 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of RNA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RNA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.